Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 18/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 18/20 | 0.76 |
| ▸ | PDE4A | P27815 | 9/20 | 0.76 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.76 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.76 |
| ▸ | GALR3 | O60755 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7426790 | 0.86 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL31123125 | 0.86 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7383314 | 0.80 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10518706 | 0.79 | PDE3B (0.67) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL31116835 | 0.79 | PDE3B (0.51) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL31116858 | 0.79 | PDE3B (0.57) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL11323239 | 0.77 | PDE3B (0.69) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10353457 | 0.77 | PDE3B (0.71) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7410994 | 0.76 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10902917 | 0.76 | PDE3B (0.79) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0178876-B1 | PYRIDAZINONE INOTROPIC AGENTS | ELI LILLY AND COMPANY (US) | 1989-09-06 | — | — | EP | claimed |
| US-4617302-A | Inotropic agents | ELI LILLY AND COMPANY (US) | 1986-10-14 | — | — | US | claimed |
| EP-0178876-A1 | Pyridazinone inotropic agents | ELI LILLY AND COMPANY (US) | 1986-04-23 | — | — | EP | claimed |
| EP-4676590-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | Zoetis Services LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20240308973-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | ZOETIS SERVICES LLC | 2024-09-19 | — | — | US | disclosed |
| WO-2024191714-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | ZOETIS SERVICES LLC (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-0178876-B1 | PYRIDAZINONE INOTROPIC AGENTS | ELI LILLY AND COMPANY (US) | 1989-09-06 | — | — | EP | disclosed |
| US-4617302-A | Inotropic agents | ELI LILLY AND COMPANY (US) | 1986-10-14 | — | — | US | disclosed |
| EP-0178876-A1 | Pyridazinone inotropic agents | ELI LILLY AND COMPANY (US) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308973-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | PDE3A, PDE3B, PDE5A | PDE3B 2/4885PDE3A 1/4885PDE4A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.